Search research articles
Contact Us
Filters
Showing results (191-200 of 201) with videos related to
Page
of 21
Sort By:
Journal of Medicinal Chemistry
|
November 17, 2015
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia
Michael J Genin, Ana B Bueno, Javier Agejas Francisco, et al.
Injury
|
April 23, 2015
Comparison of atriocaval shunting with perihepatic packing versus perihepatic packing alone for retrohepatic vena cava injuries in a swine model
Joshua P Hazelton, Rachel L Choron, Gregory M Dodson, et al.
Diabetes
|
September 9, 2010
Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets
Kyle W Sloop, Francis S Willard, Martin B Brenner, et al.
The Journal of Biological Chemistry
|
May 5, 2007
Specific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage disease
Kyle W Sloop, Aaron D Showalter, Amy L Cox, et al.
Journal of Physics. Condensed Matter : an Institute of Physics Journal
|
August 12, 2011
Chemical vapour deposition synthetic diamond: materials, technology and applications
R S Balmer, J R Brandon, S L Clewes, et al.
Diabetes
|
May 28, 2005
Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism
Lynnetta M Watts, Vara Prasad Manchem, Thomas A Leedom, et al.
The American Journal of Cardiology
|
December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Jean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
Diabetes & Vascular Disease Research
|
October 30, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
Jean-Charles Fruchart, Frank M Sacks, Michel P Hermans, et al.
The Journal of Biological Chemistry
|
June 19, 2015
Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo
Timothy B Durham, James L Toth, Valentine J Klimkowski, et al.
The Journal of Clinical Investigation
|
June 3, 2004
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors
Kyle W Sloop, Julia Xiao-Chun Cao, Angela M Siesky, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 201) with videos related to
Sort By:
Page
of 21
Journal of Medicinal Chemistry
|
November 17, 2015
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia
Michael J Genin, Ana B Bueno, Javier Agejas Francisco, et al.
Injury
|
April 23, 2015
Comparison of atriocaval shunting with perihepatic packing versus perihepatic packing alone for retrohepatic vena cava injuries in a swine model
Joshua P Hazelton, Rachel L Choron, Gregory M Dodson, et al.
Diabetes
|
September 9, 2010
Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets
Kyle W Sloop, Francis S Willard, Martin B Brenner, et al.
The Journal of Biological Chemistry
|
May 5, 2007
Specific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage disease
Kyle W Sloop, Aaron D Showalter, Amy L Cox, et al.
Journal of Physics. Condensed Matter : an Institute of Physics Journal
|
August 12, 2011
Chemical vapour deposition synthetic diamond: materials, technology and applications
R S Balmer, J R Brandon, S L Clewes, et al.
Diabetes
|
May 28, 2005
Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism
Lynnetta M Watts, Vara Prasad Manchem, Thomas A Leedom, et al.
The American Journal of Cardiology
|
December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Jean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
Diabetes & Vascular Disease Research
|
October 30, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
Jean-Charles Fruchart, Frank M Sacks, Michel P Hermans, et al.
The Journal of Biological Chemistry
|
June 19, 2015
Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo
Timothy B Durham, James L Toth, Valentine J Klimkowski, et al.
The Journal of Clinical Investigation
|
June 3, 2004
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors
Kyle W Sloop, Julia Xiao-Chun Cao, Angela M Siesky, et al.
Page
of 21